Evidence map›Paper›PMID 33575961›Full record

ArticleStem cell reviews and reports2021

Results and Prospects of Using Activator of Hematopoietic Stem Cell Differentiation in Complex Therapy for Patients with COVID-19.

V Kh Khavinson, B I Kuznik, S V Trofimova, V A Volchkov, S A Rukavishnikova, O N Titova, T A Akhmedov, A V Trofimov, V V Potemkin, E Magen

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell reviews and reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 12 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

V Kh KhavinsonSaint Petersburg Institute of Bioregulation and Gerontology, Dynamo, 3, Saint Petersburg, 197110, Russia.
B I KuznikChita State Medical Academy, M.Gorkiy Str., 39a, Chita, 672000, Russia.
S V TrofimovaSaint Petersburg Institute of Bioregulation and Gerontology, Dynamo, 3, Saint Petersburg, 197110, Russia. dr.s.trofimova@gmail.com.ORCID 0000-0002-5190-1824
V A VolchkovCity Multi-Field Hospital №2, Uchebniy Alley, 5, Saint Petersburg, 194354, Russia.
S A RukavishnikovaCity Multi-Field Hospital №2, Uchebniy Alley, 5, Saint Petersburg, 194354, Russia.
O N TitovaFirst Pavlov State Medical University of St. Petersburg, Lev Tolstoy Str., 6-8, Saint Petersburg, 197022, Russia.
T A AkhmedovCity Multi-Field Hospital №2, Uchebniy Alley, 5, Saint Petersburg, 194354, Russia.
A V TrofimovSaint Petersburg Institute of Bioregulation and Gerontology, Dynamo, 3, Saint Petersburg, 197110, Russia.
V V PotemkinCity Multi-Field Hospital №2, Uchebniy Alley, 5, Saint Petersburg, 194354, Russia.
E MagenBen-Gurion University, Ashdod, Israel.
First Pavlov State Medical University of St. Petersburg · RUSt. Petersburg Institute of Bioregulation and Gerontology · RUBen-Gurion University of the Negev · ILChita State Academy of Medicine · RUCity Hospital No. 40 · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The paper presents the results of a standard and complex treatment method using the peptide drug thymus thymalin in patients with COVID-19. One of the mechanisms of the immunomodulatory effect of thymalin is considered to be the ability of this peptide drug to influence the differentiation of human hematopoietic stem cells (HSCs). It was found that, as a result of standard treatment, patients in the control group showed a decrease in the concentration of the pro-inflammatory cytokine IL-6, C-reactive protein, D-dimer. The addition of thymalin to standard therapy accelerated the decline in both these indicators and the indicators of the T cell system. This has helped reduce the risk of blood clots in COVID-19 patients. The revealed properties of the thymus peptide preparation are the rationale for its inclusion in the complex treatment of coronavirus infection. Peptideswith potential biological activity against SARS-CoV-2 virus [29]. Note: Nitrogen atoms are shown in blue, oxygen atoms - in red, carbon atoms - in gray, hydrogen atoms - in white, and phosphorus atoms - in yellow.

Indexed as

COVID-19 Drug TreatmentCell DifferentiationCOVID-19CytokinesHematopoiesisHematopoietic Stem CellsHumansSARS-CoV-2Thymus GlandThymus HormonesCytokinesthymalinThymus HormonesCOVID-19HemostasisImmunityPeptidesStandard therapyThymalin

Identifiers

PMID33575961
PMCPMC7877506
OpenAlexW3128194661

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.